ArticleScientific reports2025
Nanocrystals as a promising approach for enhancing solubility and dissolution of etoricoxib using Box-Behnken design.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transdermal patches loaded with etoricoxib nanocrystals as a remedy and prophylactic approach against progression of knee osteoarthritis.Drug delivery and translational research · 2026Article
- The Role and Potential of Nanotechnology in Improving Solubility and Enhancing Bioavailability.Pharmaceutics · 2026Review
- The Development and Optimisation of a Spinosin Solid-Dispersion-Based Functional Dairy Beverage and Its Sleep-Promoting Effects in Mice.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor solubility of drugs represents a major obstacle against drug delivery, so pharmaceutical industry is exploring the use of nanocrystals as a promising approach to enhance the bioavailability of those medications with improving their pharmacokinetics. This study aims to improve etoricoxib properties via nanocrystal form using an acid-base precipitation method. This method is simple, environment- friendly, and prefers non-organic solvents and chemicals, thus overcoming challenges in developing dosage forms. Prepared nanocrystals were optimized for several factors such as stabilizer type and concentration, amount of drug, time and speed of homogenization. FT-IR, DSC, X-ray diffraction, and TEM characterizations were conducted on the optimized nanocrystal formula. The findings showed a successful inclusion of etoricoxib as nanocrystals with a mean particle size of 210.30 ± 10.20 nm, PDI of 0.277 ± 0.01, and a zeta potential of - 74.10 ± 0.61 mV. TEM imaging revealed well-defined cubic-shaped nanoparticles, indicating morphological uniformity and excipient compatibility. Solubility studies demonstrated notable enhancement in the aqueous solubility of etoricoxib nanocrystals (137.75 ± 1.34 µg/mL) compared to the pure drug (87.70 ± 1.41 µg/mL). Additionally, the nanocrystals exhibited rapid dissolution profile, achieving 91.49 ± 0.01% drug release within 5 min. These results suggest that using nanocrystals to improve the aqueous solubility and dissolution of medications with poor solubility is a potential strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.